Patient characteristics and treatment outcomes according to FCGR3A and FCGR2A alleles
. | FCGR3A . | . | . | . | FCGR2A . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | FF . | FV . | VV . | P . | HH . | HR . | RR . | P . | ||||
| No. patients (%) | 6 (5) | 54 (48) | 53 (47) | 60 (56) | 40 (37) | 8 (7) | ||||||
| Sex, no. women/men | 3/3 | 27/27 | 19/34 | NS | 25/35 | 16/24 | 5/3 | NS | ||||
| Age, median y (range) | 55 (45-76) | 60 (25-83) | 61 (18-84) | NS | 61 (18-82) | 60.5 (25-84) | 60 (24-83) | NS | ||||
| Disease, no (%) | ||||||||||||
| Stages 3, 4 | 2 (33) | 21 (39) | 22 (41) | NS | 23 (38) | 17 (43) | 3 (38) | NS | ||||
| Elevated LDH | 2 (33) | 29 (54) | 27 (51) | NS | 33 (55) | 19 (48) | 3 (38) | NS | ||||
| Extranodal | 2 (33) | 22 (41) | 25 (47) | NS | 32 (68) | 13 (28) | 2 (25) | .066 | ||||
| Age, at least 60 y | 2 (33) | 29 (54) | 28 (53) | NS | 32 (53) | 21 (53) | 4 (50) | NS | ||||
| ECOG of at least 2 | 2 (33) | 10 (19) | 8 (15) | NS | 10 (17) | 9 (23) | 1 (13) | NS | ||||
| IPI score, no. (%) | ||||||||||||
| 0-2 | 5 (83) | 36 (67) | 34 (65) | NS | 39 (66) | 27 (67) | 6 (62) | NS | ||||
| 3-5 | 1 (17) | 18 (33) | 18 (35) | 20 (34) | 13 (33) | 3 (38) | ||||||
| Regimen | ||||||||||||
| R-CHOP, no. (%) | 4 (67) | 40 (74) | 32 (60) | NS | 41 (68) | 26 (65) | 5 (63) | NS | ||||
| R-CHOP + IFRT, no. (%) | 2 (33) | 14 (26) | 21 (40) | 19 (32) | 14 (35) | 3 (37) | ||||||
| Cycles, R-CHOP, no. (range) | 5 (2-8) | 6 (2-8) | 6 (1-8) | NS | 6 (1-8) | 6 (1-8) | 5 (2-6) | NS | ||||
| Response, no. (%) | ||||||||||||
| Evaluable | 6 (100) | 53 (98) | 51 (96) | 59 (98) | 38 (95) | 8 (100) | ||||||
| CR | 3 (50) | 42 (79) | 45 (88) | .002* | 52 (88) | 29 (76) | 5 (63) | .178† | ||||
| PR | 0 (0) | 6 (11) | 5 (10) | 4 (7) | 6 (16) | 1 (13) | ||||||
| SD/PD | 3 (50) | 5 (9) | 1 (2) | 3 (5) | 3 (8) | 2 (25) | ||||||
| ORR (CR + PR) | 3 (50) | 48 (90) | 50 (98) | <.001 | 56 (95) | 35 (92) | 6 (75) | .137 | ||||
| Survival, no. (%) | ||||||||||||
| Relapse | 3 (50) | 7 (13) | 12 (22) | NS | 12 (20) | 6 (15) | 2 (25) | NS | ||||
| Death | 1 (17) | 5 (9) | 7 (13) | NS | 6 (10) | 4 (10) | 1 (13) | NS | ||||
. | FCGR3A . | . | . | . | FCGR2A . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | FF . | FV . | VV . | P . | HH . | HR . | RR . | P . | ||||
| No. patients (%) | 6 (5) | 54 (48) | 53 (47) | 60 (56) | 40 (37) | 8 (7) | ||||||
| Sex, no. women/men | 3/3 | 27/27 | 19/34 | NS | 25/35 | 16/24 | 5/3 | NS | ||||
| Age, median y (range) | 55 (45-76) | 60 (25-83) | 61 (18-84) | NS | 61 (18-82) | 60.5 (25-84) | 60 (24-83) | NS | ||||
| Disease, no (%) | ||||||||||||
| Stages 3, 4 | 2 (33) | 21 (39) | 22 (41) | NS | 23 (38) | 17 (43) | 3 (38) | NS | ||||
| Elevated LDH | 2 (33) | 29 (54) | 27 (51) | NS | 33 (55) | 19 (48) | 3 (38) | NS | ||||
| Extranodal | 2 (33) | 22 (41) | 25 (47) | NS | 32 (68) | 13 (28) | 2 (25) | .066 | ||||
| Age, at least 60 y | 2 (33) | 29 (54) | 28 (53) | NS | 32 (53) | 21 (53) | 4 (50) | NS | ||||
| ECOG of at least 2 | 2 (33) | 10 (19) | 8 (15) | NS | 10 (17) | 9 (23) | 1 (13) | NS | ||||
| IPI score, no. (%) | ||||||||||||
| 0-2 | 5 (83) | 36 (67) | 34 (65) | NS | 39 (66) | 27 (67) | 6 (62) | NS | ||||
| 3-5 | 1 (17) | 18 (33) | 18 (35) | 20 (34) | 13 (33) | 3 (38) | ||||||
| Regimen | ||||||||||||
| R-CHOP, no. (%) | 4 (67) | 40 (74) | 32 (60) | NS | 41 (68) | 26 (65) | 5 (63) | NS | ||||
| R-CHOP + IFRT, no. (%) | 2 (33) | 14 (26) | 21 (40) | 19 (32) | 14 (35) | 3 (37) | ||||||
| Cycles, R-CHOP, no. (range) | 5 (2-8) | 6 (2-8) | 6 (1-8) | NS | 6 (1-8) | 6 (1-8) | 5 (2-6) | NS | ||||
| Response, no. (%) | ||||||||||||
| Evaluable | 6 (100) | 53 (98) | 51 (96) | 59 (98) | 38 (95) | 8 (100) | ||||||
| CR | 3 (50) | 42 (79) | 45 (88) | .002* | 52 (88) | 29 (76) | 5 (63) | .178† | ||||
| PR | 0 (0) | 6 (11) | 5 (10) | 4 (7) | 6 (16) | 1 (13) | ||||||
| SD/PD | 3 (50) | 5 (9) | 1 (2) | 3 (5) | 3 (8) | 2 (25) | ||||||
| ORR (CR + PR) | 3 (50) | 48 (90) | 50 (98) | <.001 | 56 (95) | 35 (92) | 6 (75) | .137 | ||||
| Survival, no. (%) | ||||||||||||
| Relapse | 3 (50) | 7 (13) | 12 (22) | NS | 12 (20) | 6 (15) | 2 (25) | NS | ||||
| Death | 1 (17) | 5 (9) | 7 (13) | NS | 6 (10) | 4 (10) | 1 (13) | NS | ||||